Randomized, placebo-controlled trial on clinical and immunologic effects of probiotic containing Lactobacillus rhamnosus R0011 and L. helveticus R0052 in infants with atopic dermatitis

Figures & data

Table I. Gender and ages of AD patients and controls.

Parameter	Treatment group (n = 30)	Placebo group (n = 28)	Normal controls (n = 13)
Males	18	17	8
Females	12	11	5
Median age (range) in months	18.43±11.94 (2–46)	18.21±10.51 (2–44)	18.23±11.42 (2–43)

Table II. Levels of specific IgE and specific IgG4 to cow's milk in serum of patients from study and control groups at day 1 and day 30.

	Treatment group (n = 30)		Placebo group (n = 28)
Parameter	Day 1	Day 30	Day 1	Day 30	Non-atopic controls (n = 13)
sIgE to cow's milk (IU/ml)	8.4±49.55	6.39±3.38	9.04±4.08	15.30±7.05	< 0.35
sIgG4 to cow's milk (μg/ml)	128.35±21.56	141.57±23.09*	195.44±24.10	209.90±20.71	< 10

*p < 0.001 (Wilcoxon matched pairs test).

Table III. Percentages of lymphocyte subsets in peripheral blood of patients from study and control groups and non-atopic controls at day 1 and day 30.

	Treatment group (n = 30) (%)		Placebo group (n = 28) (%)
Lymphocyte subset	Day 1	Day 30	Day 1	Day 30	Non-atopic controls (n = 13) (%)
CD4CD45RA+	59.88±6.98	54.69±7.41	41.77±12.10	36.67±10.46†	64.14±4.38
CD4CD45RA+RO+	19.37±1.66	13.39±1.34*†	19.74±3.46	14.01±2.13	21.22±3.32
CD4CD45RO+	42.77±4.42†	45.83±4.72†	51.86±8.03†	55.32±7.18†	23.26±2.72

*p < 0.05 in comparison with levels at day 1 (Wilcoxon matched pairs test).

†p < 0.05 in comparison with non-atopic controls (unpaired t test with Welch correction).